Stock Events

Ocean Biomedical 

$1.13
48
+$0.03+2.73% Today

Statistics

Day High
-
Day Low
-
52W High
7.79
52W Low
0.52
Volume
136,040
Avg. Volume
156,403
Mkt Cap
39.5M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

15AprExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q1 2024
-0.53
-0.21
0.11
0.43
Expected EPS
-0.15
Actual EPS
-0.53

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OCEA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap46.43B
Moderna is a leader in mRNA technology, directly competing in the biotech space for innovative treatments, similar to Ocean Biomedical's focus on novel therapies.
BioNTech
BNTX
Mkt Cap20.32B
BioNTech competes in the development of new therapies and vaccines, including mRNA technology, overlapping with Ocean Biomedical's research areas.
Pfizer
PFE
Mkt Cap169.83B
Pfizer is a large pharmaceutical company with a broad portfolio that includes innovative treatments and vaccines, competing for market share in the biopharmaceutical field.
Novavax
NVAX
Mkt Cap1.94B
Novavax is involved in the development of vaccines for infectious diseases, competing in the same space as Ocean Biomedical's focus on novel healthcare solutions.
Gilead Sciences
GILD
Mkt Cap90.4B
Gilead Sciences is a biopharmaceutical company that develops and markets treatments for life-threatening diseases, directly competing with Ocean Biomedical's mission.
Regeneron Pharmaceuticals
REGN
Mkt Cap114.81B
Regeneron Pharmaceuticals focuses on developing and commercializing treatments for serious medical conditions, competing in the innovative therapy space.
Vertex Pharmaceuticals
VRTX
Mkt Cap126.85B
Vertex Pharmaceuticals is known for creating novel therapies for treating serious diseases, directly competing with Ocean Biomedical's focus areas.
AMGEN
AMGN
Mkt Cap177.72B
Amgen is a biotech firm that develops innovative human therapeutics, competing in the same space as Ocean Biomedical for breakthrough treatments.
Biogen
BIIB
Mkt Cap32.96B
Biogen focuses on developing therapies for neurological diseases, competing with Ocean Biomedical's approach to addressing unmet medical needs.
Novartis
NVS
Mkt Cap232.42B
Novartis is a global healthcare company that offers a wide range of healthcare products, including innovative medicines that compete with Ocean Biomedical's offerings.

About

Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.
Show more...
CEO
Employees
9
Country
US
ISIN
US67644C1045
WKN
000A3D2GJ

Listings